ViCentra
PrivateLast Round
Series D
Extension
Jan 8, 2026
Total Funding Raised
$207.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ViCentra operates in Healthcare & Life Sciences and is based in Utrecht. Its latest recorded funding round was a Series D Extension round in January 2026.
ViCentra is a medical device company that develops and manufactures the Kaleido insulin patch pump system, a small and light wearable device designed for people with diabetes.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT
Business Model
B2C
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ViCentra Comparables
Compare ViCentra with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MicroTech | 81% | |
| EOFlow Co., Ltd. | 80% | |
| Terumo Corporation | 76% |
For institutional investors. Book with your work email.
ViCentra Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D Extension | Jan 8, 2026 | ||||
| Series D | Sep 3, 2025 | ||||
| Series C | Dec 16, 2021 | ||||
| Corporate Funding | Jun 30, 2020 | ||||
| Series B | Jan 16, 2016 |
For institutional investors. Book with your work email.
ViCentra Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kreos Capital | Corporate Funding |
| Venturing Tech | Series D, Series D Extension |
| EQT Life Sciences | Series C, Series D, Corporate Funding, Series B |
| Invest-NL | Series C, Series D, Corporate Funding |
| ROM Utrecht Region | Series D, Series D Extension |
| Kreos Capital | Corporate Funding |
| Partners in Equity | Series D, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 4, 2026
Mediq named as a distribution partner.
- May 4, 2026
Kaleido system integrates with Diabeloop's DBLG1/DBLG2 algorithm.
For institutional investors. Book with your work email.
ViCentra Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ViCentra's valuation, stock price, and market status.
Is ViCentra a public or private company?
ViCentra is a private company.
What is the current stock price of ViCentra?
ViCentra is a private company, so its shares have no public market price. Caplight tracks ViCentra's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ViCentra worth (valuation)?
Valuation information for ViCentra is not publicly available.
Can I buy ViCentra stock?
ViCentra shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ViCentra's last funding round?
ViCentra's most recent funding round was Series D Extension on January 8, 2026.
Who are the main investors in ViCentra?
Key investors in ViCentra include EQT Life Sciences, Invest-NL, Partners in Equity, Inkef Capital, Innovation Industries.
Will ViCentra IPO soon?
No public IPO plans have been announced for ViCentra.
How can I track ViCentra secondary market activity?
Caplight tracks bids, offers, and trades in ViCentra's shares on secondary markets.